The assessment of miR-181b on acute myelogenous leukemia patients treatment resistance

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 413

متن کامل این مقاله منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل مقاله (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

IPMCMED03_069

تاریخ نمایه سازی: 6 خرداد 1398

چکیده مقاله:

Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder characterized by the rapid growth and abnormal accumulation of granulocyte or monocyte precursors in bone marrow and blood that eventually interferes with the production of normal blood cells. There are some karyotypic changes and somatic mutations in AML that are associated with the risk of relapse. miRNAs are the epigenetic regulators of progression and proliferation of the cell cycle and change in the expression of their genes can play an important role in malignancies and cancer cell behaviors. miRNA՚s genes false expression is involved in AML. According to previous studies, it has been shown that modified miRNA-181 gene expression which itself has different types is associated with clinical symptoms of AML. So in our research, we decided to examine the expression of miRNA-181b gene in the afflicted people of AML. In this trial, individuals were divided into 3 groups of 25, including healthy people, AML patients with drug-sensitive and AML patients with drug-resistant and their peripheral blood samples were taken. The exclusive primer was first designed for the molecular investigations. The total RNA of tumor and non-tumor tissues was extracted using TRIzol, and RT of miRNA into cDNA was performed using the Reverse Transcription kit according to the manufacturer s protocols. Reverse transcription polymerase chain reaction (RT-PCR) was performed to detect the expression levels of miR-181b in samples. The results showed that the level of miRNA181b expression in AML patients, who were resistant to drugs and those who were sensitive to the drugs, was significantly reduced compared to the control group which was significantly different (p<0/05) . There wasn’t significant relationship between drug-resistant and drug- sensitive patients. It is suggested that miRNA-181b could be used as a biochemical marker for the diagnosis and prediction of AML and even its treatment.

کلیدواژه ها:

نویسندگان

Azar Bahadori

Department of Genetics Parand Branch Islamic Azad University, Parand, Iran

Mitra Heydari Nasrabadi

Department of Genetics Parand Branch Islamic Azad University, Parand, Iran

Farhad Shahi

Department Internal Medicine, Hematology and Medical Oncology Ward, Cancer Research Center, Cancer institute, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Tehran, Iran